Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

program for ENMD-2076 is expanding with the addition of the myeloma clinical study announced earlier and with this new study in patients with leukemia. Also, plans are underway to expand the solid tumor study at the maximum tolerated dose of ENMD-2076 to further define the objectives of safety, pharmacokinetics and antitumor activity. We believe the current clinical program allows us to quickly add new patients to establish the potential of ENMD-2076 and provide a focus for Phase 2 development. These data serve as a foundation to continue discussions with potential development partners for ENMD-2076."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... HealthTronics, Inc. , a leading ... and services, has signed a distribution agreement through ... for its high precision laser technology. ... mobile, surgical technology—offering more choices for healthcare providers ... will make available Clinicon’s FDA-cleared SureLase™ CO2 Laser ...
(Date:9/19/2014)... 19, 2014  InterMune, Inc. (Nasdaq: ITMN ... of Understanding to settle the litigation in the Delaware ... of Merger dated as of August 22, 2014, among ... As one term of the Memorandum of Understanding, the ... in the attached exhibit reflecting the amendment to the ...
(Date:9/19/2014)... at NYU Langone Medical Center have found a way ... for turning adult cells into so-called pluripotent stem cells ... the new technique in mice, the researchers increased the ... by more than 20-fold compared with the standard method. ... thus should generally accelerate research aimed at using stem ...
(Date:9/19/2014)... 19, 2014 Follow us ... to revolutionize the world has attracted diverse players ... small start-ups. The early years of nanotechnology development ... due to the high risks involved, which deterred ... for this evolving technology have been growing over ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... Ferring Pharmaceuticals Inc.,has announced that its hyaluronic ... the title sponsor of the EUFLEXXA National,Senior Games ... Year,Award., "This is such a tremendous opportunity ... Alex Drigan, Product Manager, EUFLEXXA(TM). "We,support all that ...
... MOUNTAIN VIEW, Calif., Jan. 28 Clontech Laboratories,Inc., ... announced the,imminent (February 20, 2008) release of its ... issue of Clontechniques, the company,s quarterly,newsletter. Based on ... Stanford, the ProteoTuner systems use a unique technology ...
... for Continued Development of CNDO103 as ... ... today,announced the publication of data demonstrating that the Bcl-2 inhibitor,Apogossypol, effectively ... than Gossypol in vivo in mice., Published online in Blood ...
Cached Biology Technology:Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 2Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 3Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award 4Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 3
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
(Date:9/18/2014)... their entire lives nestling in the protective tentacles of ... they sometimes travel hundreds of kilometres across the open ... fish has been predicted, this is the first time ... populations has been observed. , Dr Steve Simpson, Senior ... University of Exeter, and colleagues from the Australian Research ...
Breaking Biology News(10 mins):How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3
... century, state-of-the-art anti-aging technologies may extend human lifespans at ... social and economic challenges, says biologist Shripad Tuljapurkar of ... advances would have major implications for the global community ... Morrison Professor of Population Studies, will give a talk ...
... Cell reports the discovery of a gene that drives ... potential new target for countermeasures against the lethal toxin, ... the potential to protect against anthrax during the late ... therapeutic value, they added. , The team found that ...
... biologist Ernst Mayr's theory of genetic revolution , introduced ... has many detractors. , Mayr believed that genes interacted ... turn led to an interaction of natural selection with ... of evolutionary change. , Detractors of the theory object ...
Cached Biology News:World faces challenge as life expectancies lengthen, scientist says 2World faces challenge as life expectancies lengthen, scientist says 3World faces challenge as life expectancies lengthen, scientist says 4Driver of anthrax toxicity could lead to late-stage therapy 2Ernst Mayr's theory illustrated in genetic epidemiology studies 2Ernst Mayr's theory illustrated in genetic epidemiology studies 3Ernst Mayr's theory illustrated in genetic epidemiology studies 4
in vitro Translation, Accessory Products...
... RNA Quantitation Kit is one of ... the quantitation of RNA in solution. ... more sensitive than absorbance measurements. As ... detected with fluorescence microplate readers and ...
Donor Horse Serum US Origin...
... added in Dec 2005 , Quantitative ... Detection from as little as 25 pg ... available for hundreds of mammalian miRNAs , ... , Ideal for validating expression profiling ...
Biology Products: